Allocating Purchase Price for a Pharma Transaction—Pfizer Acquires Medivation (Part I)

In August 2016, Pfizer announced it would acquire Medivation for $14 billion.  The transaction made headlines for how the size of the deal escalated over a period of approximately six months prior to the announcement.  Sujan Rajbhandary, senior member of Mercer Capital’s Financial Reporting Valuation Group, presents in this blog post (and Part II) a broad outline of the transaction and explore what a potential purchase price allocation would look like.

To read the full article in Mercer Capital’s Financial Reporting Blog, click: Allocating Purchase Price for a Pharma Transaction—Pfizer Acquires Medivation (Part I).

This article is republished from Mercer Capital’s Financial Reporting Blog.  It is reprinted with permission.  To subscribe to the blog, visit: http://mercercapital.com/category/financialreportingblog/.